Selank Dosing Protocol

Selank is a lab-made peptide that reduces anxiety and sharpens mental performance — without the sedation, dependence, or brain fog caused by conventional anti-anxiety medications like benzodiazepines. Developed in Russia by the Institute of Molecular Genetics and the Zakusov Research Institute of Pharmacology, Selank (also called TP-7) is based on tuftsin, a small immune-related molecule found naturally in your blood. The researchers modified tuftsin to make it more stable and longer-lasting in the brain.

Selank is a seven-amino-acid peptide. Despite being cleared from the bloodstream quickly (plasma half-life of about 2–10 minutes), its calming and focus-enhancing effects last 12–24 hours. This extended duration comes from a structural tail (Pro-Gly-Pro) that was added to the end of the molecule, which slows breakdown and triggers lasting changes in brain chemistry — particularly in the systems that regulate anxiety and mood.

Selank is approved in Russia for generalized anxiety disorder (GAD) and neurasthenia, where it's available as a nasal spray. In Russian clinical trials, Selank matched the anxiety-reducing power of benzodiazepine medications — but also boosted energy and mild cognitive performance, effects that benzodiazepines don't provide. Selank has been in clinical use in Russia since the 1990s.

This compound is not FDA-approved. All information on this page is for educational and research reference purposes only.

Selank works through multiple brain pathways at once — calming overactive anxiety circuits, supporting the brain chemicals that regulate mood and focus, promoting brain-cell growth, stabilizing your body's natural calming molecules, and modulating immune signaling. This multi-pathway approach is what sets Selank apart from single-mechanism anti-anxiety drugs. Here's how each pathway contributes.

The table below covers two Selank dosing approaches. The top rows (labeled "SubQ") show the community-derived subcutaneous protocol at 250–500 mcg/day — this is what most research users follow for daily anxiety support and focus. The bottom rows (labeled "Intranasal") show the nasal-spray protocols from Russian clinical practice, where daily doses are higher (600–2,700 mcg/day). Both include cycle-off periods.

Injection site reactions: Subcutaneous administration may cause mild transient redness or irritation. Rotating injection sites (abdomen, thighs, upper arms) helps reduce local irritation.

Nasal irritation (intranasal route): Some users report mild stinging or dryness when using intranasal formulations. Alternating nostrils and using saline moisturization may reduce irritation.

Headache: Mild headaches may occur during the first few dosing days and often resolve with continued use or dose reduction.

FDA immunogenicity warning: The FDA has flagged a theoretical immunogenicity risk for compounded Selank in certain administration contexts due to limited FDA-regulated human safety data. This warning reflects evidence gaps rather than a documented Russian clinical safety signal.

Discontinuation profile: Published Russian clinical data do not report meaningful discontinuation rates due to adverse effects and describe Selank as well tolerated.

Evidence quality note: Most safety evidence comes from Russian clinical studies; large Western trials with FDA-standard long-term safety reporting are still absent.

For a cross-class safety comparison, see the PepPal Peptide Side Effects Guide.

The table below summarizes Selank's published human research. The headline finding: in two separate trials (totaling over 120 patients with anxiety disorders), Selank matched the anxiety-reducing effects of benzodiazepine medications — but also provided energy and cognitive benefits that benzodiazepines don't deliver. Because Selank was developed in Russia, these studies were published in Russian medical journals rather than Western publications like NEJM or Lancet.

Selank's clinical development has been conducted within the Russian pharmaceutical research system, with multiple human studies across generalized anxiety disorder, neurasthenia, phobic-anxiety disorders, and somatoform disorders. Published data consistently report anxiolytic effects comparable to benzodiazepine references without the standard sedation-dependence profile. Selank has been approved for Russian clinical use since the 1990s. As of April 2026, no ClinicalTrials.gov-registered FDA-style phase 1-3 development program exists, and the absence of Western clinical validation remains the main evidence limitation.

Selank, Semax, and benzodiazepines all address anxiety and cognitive function, but through different pathways — and they're not interchangeable.

Choose Selank if your main goal is calming anxiety without sedation or dependence. Selank provides benzodiazepine-level anxiety relief plus a mild boost to focus and memory — making it the best choice for people who want to feel calmer and sharper.

Choose Semax if cognitive performance and brain protection are your primary goals. Semax is stronger on the focus/neuroprotection side and is better suited for users whose anxiety is secondary to cognitive goals.

Choose a benzodiazepine (e.g., Diazepam) if you need fast, proven anxiety relief through the conventional medical system. Benzodiazepines are FDA-approved and widely prescribed — but carry well-documented risks of sedation, memory impairment, tolerance, and dependence.

Selank and Semax are frequently paired in the Russian Nootropic Stack for combined calm-plus-focus support. Dose ranges, reconstitution math, and cycling strategies differ for each compound.

See the Semax protocol page for compound-specific guides.